Analyst Ratings for Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 Wall Street analysts have provided ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), with 2 bullish, 1 somewhat bullish, and 1 indifferent. The average price target is $194.0, representing an upside from the current price of $114.38, but this is a 2.35% decrease from the previous target of $198.67.
November 29, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a positive outlook on JAZZ with an average price target of $194, suggesting a significant upside from the current price, although the target is slightly lower than the previous one.
The positive ratings from analysts, with most leaning towards bullish and somewhat bullish, indicate a strong confidence in the stock's potential growth. The average price target suggests a substantial upside, which could influence investor sentiment and drive short-term price movement upwards. The slight decrease in the target price may slightly temper expectations but doesn't significantly alter the overall positive sentiment.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100